Inflarx NV is primarily active in the pharmaceutical industry.

The main competitors of Inflarx NV in the market are pharmaceutical companies such as Regeneron Pharmaceuticals, Novartis AG, and Roche Holding AG. These companies are also engaged in the development and commercialization of various therapeutics targeting inflammatory diseases. Inflarx NV, based in Germany, focuses on the development of innovative antibody therapeutics to treat debilitating and rare inflammatory diseases. With their cutting-edge research and development efforts, Inflarx NV competes against these industry giants to offer effective treatment options and bring advancements to the field of inflammatory diseases.

Inflarx NV is a biopharmaceutical company founded in Jena, Germany, in 2007. The company focuses on developing novel therapeutics for patients suffering from severe inflammatory diseases. Inflarx NV specializes in the field of complement immunology, targeting the activation and regulation of complement, a part of the immune system responsible for inflammation. With a dedicated team of researchers and scientists, Inflarx NV has made significant advancements in developing potential treatments for conditions such as hidradenitis suppurativa, ANCA-associated vasculitis, and pyoderma gangrenosum. The company's commitment to innovation and improving patients' lives has positioned Inflarx NV as a leading player in the biopharmaceutical industry.

Inflarx NV has achieved significant milestones in its journey. Some notable accomplishments include the successful completion of clinical trials for its lead product candidate, IFX-1, which has shown promising results in treating various inflammatory diseases. In addition, the company has secured important partnerships and collaborations with leading pharmaceutical companies, further enhancing its research and development capabilities. Furthermore, Inflarx NV has obtained regulatory approvals for its products in several key markets, paving the way for potential commercialization. These achievements demonstrate the company's commitment to addressing unmet medical needs and its potential to deliver value to both patients and investors.

Inflarx NV, a biopharmaceutical company, is primarily present in various countries and regions worldwide. Its presence can be observed in North America, Europe, Asia-Pacific, and other key global markets. Inflarx NV's operations and strategic focus extend across multiple regions, allowing it to cater to a diverse and widespread customer base.

Inflarx NV represents core values of innovation, perseverance, and scientific excellence. The company is committed to improving the lives of patients by developing revolutionary therapies to target inflammation and rare diseases. Inflarx NV prioritizes rigorous research and development processes to deliver effective treatments that address unmet medical needs. With a dedicated team of professionals, Inflarx NV strives to contribute to the advancement of healthcare by leveraging cutting-edge technologies and collaborations with key stakeholders. The company's corporate philosophy revolves around a patient-centric approach and a strong commitment to driving meaningful impact in the field of immunology and inflammatory diseases.

Analysts currently set an average price target of 9.49 EUR for the InflaRx stock (median: 6.20 EUR), implying +414.4 % versus the latest price. The consensus is based on 14 analyst ratings.

InflaRx Analyst Price Targets 2026

14 analysts currently rate the InflaRx stock: 11 recommend buying, 3 holding and 0 selling. For 2026, analysts expect InflaRx to generate revenue of 15,415.00 EUR and earnings per share of -0.30 EUR.

InflaRx Analyst Price Targets 2026

The InflaRx share (IFRX) is listed on 8 stock exchanges, including: NYSE (IFRX), NASDAQ (IFRX), XETRA (IF0.DE), Frankfurt (IF0), München (IF0.MU), Stuttgart (IF0.SG), Düsseldorf (IF0.DU), Berlin (IF0.BE).

The company Inflarx NV is a biopharmaceutical company that specializes in the discovery and development of novel therapeutics for inflammatory diseases and cancer. It is headquartered in Jena, Germany and listed on the NASDAQ stock exchange. Inflarx's business model focuses on identifying and developing medications and therapeutics for the treatment of inflammatory diseases such as severe skin inflammation, rheumatoid arthritis, systemic lupus erythematosus, and cancer. The company aims to modulate inflammatory reactions in order to enable healing. It focuses on the development of selective antibodies that block specific signaling pathways in the immune system and reduce inflammation. The company's main drug is the highly selective anti-C5aR antibody Vilobelimab, which has shown promise in clinical studies for the treatment of autoimmune diseases and rare blood disorders. Inflarx is an innovative company that places a strong emphasis on research and development, as well as collaboration with renowned academic and industrial research institutions. It works closely with the Medical University of Vienna, Charité Berlin, Yale University, and Utrecht University to develop new insights and technologies. In addition to its main product Vilobelimab, Inflarx also has a pipeline of other therapeutics in the development phase. The company is currently developing another anti-C5aR antibody, IFX-2, which is in phase 2 studies and is intended for the treatment of Pyoderma Gangraenosum and Hidradenitis Suppurativa. Furthermore, Inflarx is actively involved in the development of small molecule inhibitors targeting the C5aR signaling pathway. The company also utilizes its broad experience and expertise to explore potential in cancer immunotherapy. Inflarx has gained recognition for its innovative research in the field of immunology and inflammatory reactions. The company has partnerships with some of the leading biotech and pharmaceutical companies such as CRISPR Therapeutics and Roivant Sciences, and has received significant investments to advance its work. As a company focused on drug development, Inflarx has a business model characterized by high research and development costs as well as regulatory costs. However, Inflarx has the potential to achieve high returns as demand increases for effective therapeutics to support the immune system in inflammatory diseases and cancer. Overall, Inflarx has positioned itself as a leading biopharmaceutical company focusing on the development of innovative anti-C5aR antibodies and other medications for the treatment of inflammatory diseases and cancer. With an impressive pipeline of work in the development phase and a visionary research community, Inflarx is well positioned to continue making significant advancements in medical research and treatment.

The expected revenue of InflaRx is 15,415.00 EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of InflaRx is -20.12 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of InflaRx is currently -6.17. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the InflaRx stock.

The price-to-sales ratio (P/S) of InflaRx is currently 8,055.75. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the InflaRx stock.

The Eulerpool Quality Score for InflaRx is 4/10.

The ISIN of InflaRx is NL0012661870. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of InflaRx is A2H7A5. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of InflaRx is IFRX. The ticker symbol is used to trade InflaRx shares on the stock exchange.

InflaRx paid dividends every year for the past 0 years.

InflaRx is assigned to the 'Health' sector.

The dividends of InflaRx are distributed in EUR.